Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03775213 · ClinicalTrials.gov registry record · NA
Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 322
- Enrollment target
NCT03775213: Completed NA study, sponsored by Duke University.
NCT03775213 is a NA study that has completed, run by Duke University. The registered enrollment target is 322 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03775213, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 322 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate a decision support tool for patients diagnosed with ductal carcinoma in situ (DCIS).
Primary Outcome
Presented to participants as a categorical item: active monitoring (AM), lumpectomy, lumpectomy with radiation, mastectomy. Recorded for analysis as binary: AM vs non-AM.
Interventions
- BEHAVIORAL Decision Support Tool with Active Monitoring
- BEHAVIORAL Decision Support Tool without Active Monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2021-10-12 |
| Est. Completion | 2022-01-31 |
| Phase | NA |
What the finished NCT03775213 record still lists
NCT03775213 is an interventional study that assigns participants to a tested intervention. The registered 322 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Decision Support Tool with Active Monitoring is the first listed.
NCT03775213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03775213 about?
NCT03775213 is a clinical study titled "Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)". The purpose of this research study is to evaluate a decision support tool for patients diagnosed with ductal carcinoma in situ (DCIS).
What is the current status of trial NCT03775213?
This trial is currently completed. It is a NA study. The enrollment target is 322 participants. The study started on 2021-10-12. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT03775213?
The interventions under investigation include: Decision Support Tool with Active Monitoring (BEHAVIORAL), Decision Support Tool without Active Monitoring (BEHAVIORAL).
Who is sponsoring clinical trial NCT03775213?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03775213's enrollment target sits among peer trials
322 315th of 2000 higher than 1,686 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI